Omega Diagnostics Group PLC Exercise of Options and Total Voting Rights (0901Z)

TIDMODX

RNS Number : 0901Z

Omega Diagnostics Group PLC

15 September 2020

15 September 2020

OMEGA DIAGNOSTICS GROUP PLC

("Omega" or the "Company" or the "Group")

Exercise of Options and Total Voting Rights

Omega Diagnostics (AIM: ODX), the medical diagnostics company focused on CD4, infectious diseases and food intolerance testing, announces that it has allotted 185,000 new ordinary shares of 4 pence each in the capital of the Company ("Ordinary Shares") following the exercise of share options by certain employees.

Application has been made to the London Stock Exchange for the 185,000 new Ordinary Shares to be admitted to trading on AIM ("Admission") and it is expected that Admission will become effective and trading will commence at 8.00 a.m. on 22 September 2020.

After Admission, the total number of Ordinary Shares in issue will be 178,678,110 and the total number of voting rights will therefore be 178,678,110 . This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the FCA's Disclosure and Transparency Rules.

The information contained within this announcement is deemed by the Company to constitute inside information stipulated under the Market Abuse Regulation (EU) No. 596/2014.The below notification is made in accordance with the requirements of the EU Market Abuse Regulation.

Contacts:

 
 Omega Diagnostics Group PLC                      Tel: [phone] 
 Colin King, Chief Executive                www.omegadiagnostics.com 
 Kieron Harbinson, Group Finance Director 
 
 
 finnCap Ltd                                      Tel: [phone] 
 Geoff Nash / Teddy Whiley (Corporate 
  Finance) 
 Alice Lane (ECM) 
 
 Walbrook PR Limited                           Tel: [phone] or 
                                                [e-mail] 
 Paul McManus                                     Mob: [phone] 
 Lianne Cawthorne                                 Mob: [phone] 
 

Notification and public disclosure of transactions by Persons Discharging Managerial Responsibilities ("PDMR") and persons closely associated with them ("PCA")

 
  Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014 
 1        Details of the person discharging managerial responsibilities/person closely associated 
-------  --------------------------------------------------------------------------------------------------------- 
 a.       Name                                               Jamie Yexley 
                                                            ------------------------------------------------------ 
 2        Reason for notification 
         -------------------------------------------------  ------------------------------------------------------ 
 a.       Position/Status                                    Operations Director 
         -------------------------------------------------  ------------------------------------------------------ 
 b.       Initial notification/                              Initial Notification 
           Amendment 
         -------------------------------------------------  ------------------------------------------------------ 
 3        Details of the issuer, emission allowance market participant, auction platform, auctioneer 
           or auction monitor 
         --------------------------------------------------------------------------------------------------------- 
 a.       Name                                               Omega Diagnostics Group Plc 
         ------------------------------------------------- 
 b.       LEI                                                2138007U9P4BTZTYIR92 
         -------------------------------------------------  ------------------------------------------------------ 
 4        Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) 
           each type of transaction; (iii) each date; and (iv) each place where transactions have been 
           conducted 
-------  --------------------------------------------------------------------------------------------------------- 
 a.       Description of                                     Ordinary shares of 4p each 
           the financial 
           instrument, type 
           of instrument                                      ISIN: GB00B1VCP282 
 
           Identification 
           Code 
         -------------------------------------------------  ------------------------------------------------------ 
 b.       Nature of the                                      Exercise of Options followed by sale of Shares 
           transaction 
         -------------------------------------------------  ------------------------------------------------------ 
 
 c.       Price(s) and                                        Price(s)                 Volume(s) 
           volume(s) 
         -------------------------------------------------   ----------------------- 
                                                              86.114p                  85,000 
                                                             -----------------------  ------------------------ 
 
 d.       Aggregated information 
   - Aggregated                                        85,000 
    Volume 
   - Price                                              86.114p 
 -------------------------------------------------  -------------------------------------------------------------- 
 e.       Date of the transaction                            22/09/2020 
         -------------------------------------------------  ------------------------------------------------------ 
 f.       Place of the                                       London Stock Exchange 
           transaction 
         -------------------------------------------------  ------------------------------------------------------ 
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

TVRSFLFMIESSELU

(END) Dow Jones Newswires

September 15, 2020 12:51 ET (16:51 GMT)